Axcella Health (NASDAQ:AXLA) shares are trading higher on Thursday, after Wedbush initiated coverage on the stock with an Outperform rating and announced a price target of $28 per share.
Axcella Health a biotechnology company involved in the research and development of novel multifactorial interventions to support health and address dysregulated metabolism. The company's pipeline comprises five programs focused on the metabolic functions of the liver, muscle, and blood.
Axcella Health shares were trading up 10.25% at $5.70 at time of publication on Thursday. The stock has a 52-week high of $15.25 and a 52-week low of $2.25.
Related Links:
UK Clears Gilead's Remdesivir For Some Coronavirus Patients
10 Biopharmaceutical Companies Trying To Cure Cancer
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
